A novel nucleoside with an oxetanosyl-N-glycoside has been recently isolated from a culture filtrate from Bacillus megaterium and named oxetanocin A (N. Shimada, S. Hasegawa, T. Harada, T. Tomisawa, A. Fujii, and T. Takita, J. Antibiot. 39:1623Antibiot. 39: -1625Antibiot. 39: , 1986. In this study, we evaluated the antiherpesvirus activity of oxetanocin A and its derivatives and found that 9-(2-deoxy-2-hydroxymethyl-,-D-erythro-oxetanosyl)guanine (OXT-G) was very potent and selective in inhibiting the replication of human cytomegalovirus (HCMV) in vitro. The median effective concentration for HCMV strain AD169 was 1.0 ,ug/ml, and that for herpes simplex virus type 2 strain 186 was 3.5 ,ug/ml. The selectivity index, based on the ratio of the median inhibitory concentration for cell growth of human diploid fibroblasts to the median effective concentration for HCMV plaque formation, was more than 300. The synthesis of HCMV-induced late polypeptides such as the 150,000-molecular-weight capsid and the 68,000-molecular-weight major matrix proteins was strongly suppressed when OXT-G (5 ,ug/ml) was added to the cultures at the beginning of infection. At this concentration of OXT-G, the amount of HCMV DNA detected in the drug-treated infected cells was less than 1/10 of that detected in the infected control cells. The results suggest that the mode of action of OXT-G is inhibition of viral replication by impairing the viral DNA synthesis.
Human cytomegalovirus (HCMV) is an important human pathogen which causes congenital cytomegalic inclusion disease, heterophile-negative mononucleosis, retinitis, and interstitial pneumonia (3, 11) . In immunocompromised individuals such as transplant recipients and patients with acquired immunodeficiency syndrome, cytomegalovirus pneumonia is a major cause of mortality (7) . While several chemotherapeutic agents are clinically available for the treatment of herpes simplex virus (HSV) and varicella-zoster virus, there are no licensed drugs against HCMV infections. At present the most promising candidate is the acyclic guanosine analog 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) (1, 8) , which is currently undergoing clinical trials for the therapy of severe HCMV infections in immunodeficient patients (2) . However, it is essential that we search for more selective and potent agents against this pathogen.
Recently, a novel nucleoside, 9-(2-deoxy-2-hydroxymethyl-f3-D-erythro-oxetanosyl)adenine (OXT-A), was isolated from a culture filtrate of Bacillus megaterium NK84-0218 (12) . This compound was the first natural product with an oxetanosyl-N-glycoside and has been found to have antiviral activities against HSV and human immunodeficiency virus (4) . In this study, we investigated the effect of OXT-A and its derivatives, including 9-(2-deoxy-2-hydroxymethyl-,-D-erythro-oxetanosyl)2-aminoadenine (2-amino-OXT-A) and 9-(2-deoxy-2-hydroxymethyl-,-D-erythro-oxetanosyl)guanine (OXT-G), against HCMV in vitro.
MATERIALS AND METHODS
Chemicals. OXT-A was obtained from a culture filtrate of B. megaterium NK84-0218 as described previously (13); and 2-amino-OXT-A, OXT-G, 9-(2-deoxy-2-hydroxymethyl-,B-Derythro-oxetanosyl)hypoxanthine (OXT-H), and 9-(2-deoxy-* Corresponding author.
2-hydroxymethyl-p-D-erythro-oxetanosyl)xanthine (OXT-X)
were produced from OXT-A by chemical and biological transformation. The chemical structures of some OXTs used in this study are shown in Fig. 1 tissue culture plates. Each of the cells was cultured at 37°C in 0.2 ml of bicarbonate-buffered minimal essential medium containing 10% fetal bovine serum in a 5% CO2 humidified incubator. The drugs were added 24 h after cultivation to make appropriate concentrations. After a further incubation at 37°C, cell growth was usually assayed by an indirect colorimetric method with slight modifications, as described by Kobori et al. (5) . In brief, after the culture medium was removed from each well, adherent cells were fixed by incubation for 2 min with 50 ,ul of methanol, mixed with 100 ,ul of 10 mM Tris hydrochloride buffer (pH 8.5) containing 0.05% methylene blue, and incubated for 30 min at room temperature. The stained cells were washed with distilled water, mixed with 200 ,ul of 3% HCl, and incubated for 24 h at room temperature to elute the methylene blue from the cells. The optical density of the HCI solution was measured at 660 nm with a microplate reader (model MR600; Dynatech Laboratories, Inc., Alexandria, Va.). The cultivation time was 72 h for PC-1 and 96 h for Detroit 551, CCD-18Co, and HepG2.
Polyacrylamide slab gel electrophoresis. Cells were labeled with [35S]methionine (10 ,uCi/ml) in methionine-free minimal essential medium, and the labeled proteins were analyzed by the method of Laemmli (6) . Samples were dissociated in 0.0625 M Tris hydrochloride (pH 6.8) containing 5% sodium dodecyl sulfate (SDS), 2% 2-mercaptoethanol, 10% glycerol, and 0.001% bromophenol blue, followed by heating at 100°C for 1 min. The acrylamide concentrations were, 8.5% for the separating gel and 3% for the stacking gel. After electrophoresis, the gels were fixed, dried, and then exposed to film (Royal X-Omat; Eastman Kodak Co., Rochester, N.Y.) at -800C. Dot blot hybridization. Infected cells were collected by centrifugation; washed with phosphate-buffered saline; and suspended in a buffer solution (pH 8.1) containing 10 mM Tris hydrochloride, 0.1 mM EDTA, and 150 mM NaCl. Cells were lysed by the addition of 1.0% SDS and digested with pronase at a concentration of 500 ,ug/ml at 37°C for 3 h. The solution was extracted 3 times with a mixture of phenol and chloroform-isoamyl alcohol (24:1) and dialyzed against 2 liters of TE solution (10 mM Tris hydrochloride, 1 mM EDTA) with several changes. The sample was treated with 100 ,ug of DNase-free RNase per ml at 37°C for 2 h and extracted with organic solvents as described above. After dialysis, DNA was precipitated with ethanol, dissolved in TE solution, and denatured by heating. Each sample was serially diluted with SSC (1 x SSC is 0.15 M NaCl plus 0.015 M sodium citrate), to yield a final volume of 100 ,ul, and each dilution was applied with suction to a 4-mm-diameter spot on a membrane (Gene Screen Plus; New England Nuclear Corp., Boston, Mass.). Prehybridization and hybridization were performed as described in the protocol of the supplier. Briefly, the membrane was prehybridized by treating it in 10 ml of the following solution; 50% formamide (deionized), 1% SDS, 1 M sodium chloride, and 10% dextran sulfate. The solution was added to a sealable plastic bag containing the membrane. The plastic bag was sealed and incubated with constant agitation for at least 6 h at 42°C. The solution containing denatured salmon sperm DNA (.100 p.g/ml) and denatured radioactive probe (XbaI fragments of HCMV DNA isolated from purified virions) was added to the bag containing the prehybridization buffer and the membrane. The plastic bag was resealed and incubated with constant agitation for 24 h at 42°C. The membrane was removed from hybridization solution, washed with SSC, allowed to dry at room temperature, and used for autoradiography.
RESULTS
Antiviral and anticellular activities of OXTs. The antiviral and anticellular activities of OXT-A and its derivatives were measured by the plaque reduction assays and cell growth inhibition tests and are expressed in terms of the median effective concentration (EC50) and the median inhibitory concentration (IC50), which were defined as the drug concentrations that reduced viral and cellular replication to 50%, respectively. The results are summarized in Table 1 1.0 and 3.5 jxg/ml, respectively. On the other hand, the IC50s for uninfected human fibroblasts such as Detroit 551 and CCD-18Co were more than 300 pug/ml. It was also shown that 2-amino-OXT-G, which can be considered a prodrug of OXT-G, had potent antiviral activity and selectivity, comparable to those of OXT-G.
Comparative efficacy of OXT-G, ACV, and DHPG against HCMV and HSV-2. The antiviral activity of OXT-G was compared with those of the known antiherpesvirus drugs ACV and DHPG. The potency of OXT-G against HCMV was almost the same as that of DHPG, but it was less active against HSV-2 (TK+) than ACV and DHPG (Table 2) . Both ACV and DHPG exhibited much less potent antiviral activities against HSV-2 (TK-). On the other hand, OXT-G was found to have about the same activities against both TKand TK+ HSV-2.
Effects of OXT-G on HCMV-induced protein and DNA synthesis. To determine the effect of OXT-G on HCMVinduced protein synthesis, SDS-polyacrylamide gel electrophoresis was performed. In control cells infected with HCMV (Fig. 2) , the high rate of synthesis of the 150,000-molecular-weight capsid (150K capsid) and the 68K major matrix proteins was observed. In HCMV-infected cells treated with OXT-G, however, the synthesis of these proteins was suppressed in a dose-related manner. At a concentration of 5 jig/ml, the synthesis of the 68K major matrix protein was reduced to less than one fifth of that of control cells, as measured with a densitometer. On the other hand, the synthesis of these late proteins was not affected at all, even at 50 ,ug of OXT-G per ml, when the drug was added 3 h before labeling.
The effect of OXT-G on HCMV DNA synthesis was determined by a dot blot hybridization technique, with 32P-labeled HCMV XbaI fragments used as probes. The drug was added to the infected cultures 1 h after infection, and the DNA was extracted from cells at 72 h postinfection. The amount of viral DNA that accumulated in infected cells was inhibited by more than 50% at 1 ,Ig of OXT-G per ml (Fig. 3) . At a concentration of 5 ,ug/ml, it was reduced to less than 1/ 10 of that of untreated infected cells.
DISCUSSION
OXT-A, a novel nucleoside from bacteria, and its derivatives were evaluated for their antiherpesvirus activities, and OXT-G was found to be the most potent compound against HCMV and HSV. The EC50 for HCMV strain AD169 was growth of human diploid fibroblasts to the EC50 for HCMV plaque formation, was greater than 300. This value of OXT-G is comparable to those of DHPG reported previously (1, 8) . Moreover, we found that the acute toxicity was very low, with its 50% lethal dose being 600 mg/kg following a single intraperitoneal injection (unpublished data). These observations indicate that OXT-G may be one of the most promising candidates as a therapeutic drug for HCMV infections.
The synthesis of HCMV-induced late polypeptides was strongly suppressed when OXT-G (5 ,ug/ml) was added to the cultures at the beginning of infection. If the addition of the drug was done several hours before labeling, at the late phase of infection, however, the protein synthesis of infected cells was not affected at all. These results indicate that OXT-G has no or little direct effect on the synthesis of RNA and protein synthesis, suggesting that the suppression of viral late protein synthesis is due to the inhibition of viral DNA synthesis. On the other hand, quantification of HCMV DNA by the dot blot hybridization method demonstrated a strong inhibition of viral DNA synthesis at 5 ,ug of OXT-G per ml. Therefore, it is suggested that the mode of action of this compound is inhibition of viral replication by impairing the viral DNA synthesis.
OXT-G exhibited equal potencies against wild-type and TK-HSV-2. This suggests that OXT-G, unlike ACV and DHPG, is a poor substrate of HSV-2 TK. At present, the precise mechanism of action of this agent remains unelucidated. However, it may be reasonable to infer that OXT-G is phosphorylated by cellular nucleoside kinases and then that OXT-GTP inhibits HCMV-induced DNA polymerase, inhibiting viral DNA synthesis. Further studies are necessary to clarify these points.
